Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reactive Skin Decontamination Lotion (RSDL) is a topical decontaminant specifically formulated to neutralize and remove chemical warfare agents (CWAs) such as nerve agents (e.g., VX, Sarin/GB, Soman/GD), blister agents (e.g., sulfur mustard/HD, Lewisite), T-2 mycotoxin, and certain toxic industrial chemicals from the skin. The active ingredients are Dekon 139 (potassium 2,3-butanedione monoximate/KBDO) and 2,3-butanedione monoxime (DAM), dissolved in a glycol-based solvent system. The mechanism of action involves rapid nucleophilic substitution reactions that neutralize organophosphorus compounds and other toxins by breaking their chemical bonds or denaturing them. RSDL is applied topically using a foam applicator; it acts within minutes to detoxify contaminants on the skin surface. It is FDA-cleared as a medical device for emergency use in chemical exposures[2][3][5][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reactive Skin Decontamination Lotion.